Comparing the cost-effectiveness of SGLT2i versus mineralocorticoid antagonists

FHS
June 19, 2023
2:43 pm

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are approved for heart failure with reduced ejection fraction (HFrEF).

Election outcome could bring big changes to Medicare

On the campaign trail, both former President Donald Trump and Vice President Kamala Harris are eager to portray themselves as guardians of Medicare.

November 5, 2024

FDA accepts Takeda’s NDA resubmission for esophagitis therapy

The resubmission aims to respond to the FDA’s prior feedback on Takeda’s original new drug application submission. Credit: Tada Images/Shutterstock.com. The US Food and Drug

September 21, 2023

Mind-altering ketamine becomes latest pain treatment, despite little research or regulation

WASHINGTON (AP) — As U.S. doctors scale back their use of opioid painkillers, a new option for hard-to-treat pain is taking root: ketamine, the decades-old surgical

November 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.